ストックスクリーナーアプリを入手
7.31
2.24%
0.16
Sage Therapeutics Inc (SAGE) 最新ニュース
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
SAGE STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sage Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Sage Therapeutics, Inc. (NASDAQ:SAGE) Sees Large Decline in Short Interest - MarketBeat
Analysts Offer Predictions for SAGE Q3 Earnings - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Issues Quarterly Earnings Results - MarketBeat
Wedbush Reiterates "Neutral" Rating for Sage Therapeutics (NASDAQ:SAGE) - MarketBeat
SAGE Therapeutics Faces Legal Challenges: Potential Impact on Financial Stability and Growth - MSN
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates - MSN
Q1 Earnings Forecast for SAGE Issued By Leerink Partnrs - MarketBeat
Scotiabank Cuts Sage Therapeutics (NASDAQ:SAGE) Price Target to $12.00 - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Price Target Cut to $8.00 by Analysts at Canaccord Genuity Group - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Receives Neutral Rating from HC Wainwright - MarketBeat
Needham & Company LLC Reaffirms "Hold" Rating for Sage Therapeutics (NASDAQ:SAGE) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out - Markets Insider
Lifshitz Law PLLC Investigates Potential Securities Violations: Sage, SMCI, ZoomInfo & GitLab Under Scrutiny - HPBL
Sage Therapeutics (NASDAQ:SAGE) Earns “Hold” Rating from Needham & Company LLC - Defense World
Sage Therapeutics (NASDAQ:SAGE) Earns “Neutral” Rating from HC Wainwright - Defense World
What is Leerink Partnrs’ Estimate for SAGE Q1 Earnings? - Defense World
SAGE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sage Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Sage Therapeutics price target lowered to $12 from $14 at Scotiabank - Yahoo Finance
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2024 Earnings Call Transcript - Insider Monkey
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y - MSN
Sage Therapeutics (SAGE) to Release Earnings on Tuesday - MarketBeat
(SAGE) Technical Data - Stock Traders Daily
SAGE Therapeutics’ Earnings Call: ZURZUVAE’s Success Amid Challenges - TipRanks
Sage Therapeutics (NASDAQ:SAGE) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Canaccord cuts Sage Therapeutics price target to $8, holds rating - MSN
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider
A Glimpse Into The Expert Outlook On Sage Therapeutics Through 7 Analysts - Benzinga
Canaccord cuts Sage Therapeutics price target to $8, holds rating By Investing.com - Investing.com South Africa
Hold Rating on SAGE Therapeutics Amid Underwhelming Sales and Strategic Uncertainties - TipRanks
Sage Therapeutics Inc (SAGE) Q4 2024 Earnings Call Highlights: S - GuruFocus.com
SG Americas Securities LLC Raises Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Cambridge Biopharma Firm Sage Therapeutics Sues Partner Biogen After Buyout Offer - Harvard Crimson
Sage Therapeutics Inc (SAGE) Q4 2024 Earnings Call Highlights: Strong Prescription Growth Amid ... - Yahoo Finance
Sage Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Sage Therapeutics Inc (SAGE) Q4 2024 Earnings Call Highlights: Strong Prescription Growth Amid ... By GuruFocus - Investing.com Canada
Sage Therapeutics Reports Strong 2024 Performance - TipRanks
Sage brushes off 'strategic alternatives' questions during earnings call - The Business Journals
Sage Therapeutics Inc. (SAGE) reports earnings - Quartz
SAGE Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
SAGE Therapeutics earnings missed by $0.06, revenue fell short of estimates - Investing.com
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation - Markets Insider
Sage Therapeutics, Inc. SEC 10-K Report - TradingView
Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates - Business Wire
Analysts Set Sage Therapeutics, Inc. (NASDAQ:SAGE) Price Target at $10.53 - MarketBeat
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):